Arm Yourself with Information
Metastatic castration-resistant prostate cancer (mCRPC) is prostate cancer that is resistant to medical (e.g. hormonal) or surgical treatments that lower testosterone, and has spread to other parts of the body. In other words, your prostate cancer has progressed on androgen deprivation* therapy (ADT) and has spread to other parts of the body.
* Androgen deprivation—A treatment to suppress or block the production or action of male hormones. (National Cancer Institute: NCI Dictionary of Cancer Terms. Bethesda, MD: National Cancer Institute. 2013. Available at www.cancer.gov/dictionary . Accessed 10/15/2013.)
The Role of Androgen in mCRPC
The male body produces male hormones called androgens. Research has shown that androgens help fuel the tumor. While not the only source, androgen is produced primarily in the testes and some is also produced by the adrenal glands, which are located above the kidneys. There are other key factors that contribute to the disease. Androgen is one of them. However, in men with metastatic castration-resistant prostate cancer, androgen is also made by an additional source — the tumor tissue itself.
Reducing the production of androgen is important to helping you and your doctor manage your illness.